Analysts Have Conflicting Sentiments on These Healthcare Companies: Aeterna Zentaris (AEZS), Delcath Systems (DCTH) and GlaxoSmithKline (GSK)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aeterna Zentaris (AEZS – Research Report), Delcath Systems (DCTH – Research Report) and GlaxoSmithKline (GSK – Research Report).

Aeterna Zentaris (AEZS)

In a report released today, Boobalan Pachaiyappan from H.C. Wainwright reiterated a Buy rating on Aeterna Zentaris, with a price target of $28.00. The company’s shares closed last Monday at $2.63.

According to TipRanks.com, Pachaiyappan is a 3-star analyst with an average return of 5.6% and a 57.1% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Spruce Biosciences, Cingulate Inc, and Brainsway.

Currently, the analyst consensus on Aeterna Zentaris is a Moderate Buy with an average price target of $28.00.

See Insiders’ Hot Stocks on TipRanks >>

Delcath Systems (DCTH)

In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Delcath Systems, with a price target of $19.00. The company’s shares closed last Monday at $6.00.

According to TipRanks.com, Thibault is a 3-star analyst with an average return of 2.3% and a 35.9% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.

Currently, the analyst consensus on Delcath Systems is a Moderate Buy with an average price target of $19.00, a 230.4% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $17.00 price target.

GlaxoSmithKline (GSK)

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline yesterday and set a price target of p1450.00. The company’s shares closed last Monday at $35.04.

According to TipRanks.com, Parry is a 3-star analyst with an average return of 4.3% and a 60.5% success rate. Parry covers the Healthcare sector, focusing on stocks such as Haleon PLC Sponsored ADR, Gilead Sciences, and Novartis.

The word on The Street in general, suggests a Moderate Sell analyst consensus rating for GlaxoSmithKline with a $19.66 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AEZS:

• Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
• Aeterna Zentaris reports Q4 revenue $2.5M vs. $1M last year
• Aeterna Zentaris announces Pharmanovia has acquired rights to GHRYVELIN
• Pharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)